AstraZeneca’s (AZN) product portfolio is segregated into four business segments: Cardiovascular and Metabolic Diseases (or CVMD), Respiratory, Oncology, and Other Products, which includes products from the infection, neuroscience, and gastrointestinal franchises.
The above chart shows segment-wise revenues for AstraZeneca over the last few quarters.
Below are the segment-wise performances for AstraZeneca’s four segments:
- The CVMD segment reported a 4% fall in revenues at constant exchange rates to ~$1.8 billion during 3Q17. The decline in revenues for the segment was driven by lower sales of Onglyza, Bydureon, Byetta, Symlin, and lower sales of legacy products such as Crestor, Seloken/Toprol-XL, and other legacy products. The decline was substantially offset by strong sales of Brilinta, Farxiga, and legacy product Atacand.
- The Oncology segment reported 19% growth in revenues at constant exchange rates to ~$1 billion during 3Q17. Growth was driven by strong sales of Iressa, Tagrisso, and Lynparza, and legacy product Faslodex, partially offset by lower sales of legacy products Casodex, Arimidex, Zoladex, and other oncology products.
- The Respiratory segment reported a 2% fall in revenues at constant exchange rates to ~$1.1 billion during 3Q17. The decline in revenues was driven by lower sales of Symbicort, Tudorza/Eklira, and other legacy products, partially offset by strong sales of Pulmicort, Daliresp, Duaklir, and new product Bevespi.
- The Other Products segment reported a 17% fall in revenues at constant exchange rates to $991 million during 3Q17. The fall was driven by lower sales of Nexium, Losec, Seroquel XR, FluMist, and other products, partially offset by strong sales of Synagis and Movantik.
The BLDRS Developed Markets 100 ADR ETF (ADRD) holds 18.5% of its total assets in the healthcare sector. ADRD holds 5.2% in Novartis AG ADR (NVS), 2.5% in Sanofi ADR (SNY), 2.2% in Novo Nordisk ADR (NVO), and 2% in AstraZeneca PLC ADR (AZN).